These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37260700)

  • 1. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.
    Tomiyama T; Suzuki R; Harada N; Tamura T; Toshida K; Kosai-Fujimoto Y; Tomino T; Yoshiya S; Nagao Y; Takeishi K; Itoh S; Kobayashi N; Ito H; Yoshio S; Kanto T; Yoshizumi T; Fukuhara T
    Front Cell Infect Microbiol; 2023; 13():1197349. PubMed ID: 37260700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB.
    Chang ZW; Goh YS; Rouers A; Fong SW; Tay MZ; Chavatte JM; Hor PX; Loh CY; Huang Y; Tan YJ; Neo V; Kam IKJ; Yeo NK; Tan EX; Huang D; Wang B; Salleh SNM; Ngoh EZX; Wang CI; Leo YS; Lin RTP; Lye DCB; Young BE; Muthiah M; Ng LFP; Rénia L;
    Front Immunol; 2023; 14():1206016. PubMed ID: 37465685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
    Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
    Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
    Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
    Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
    Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
    Front Immunol; 2022; 13():832501. PubMed ID: 35281023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
    Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant.
    Del Mastro A; Picascia S; D'Apice L; Trovato M; Barba P; Di Biase I; Di Biase S; Laccetti M; Belli A; Amato G; Di Muro P; Credendino O; Picardi A; De Berardinis P; Del Pozzo G; Gianfrani C
    Viruses; 2023 May; 15(5):. PubMed ID: 37243218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination.
    Kurahashi Y; Furukawa K; Sutandhio S; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
    J Infect Dis; 2022 Oct; 226(8):1391-1395. PubMed ID: 35512332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
    Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
    Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients.
    Davidov Y; Indenbaum V; Atari N; Kliker L; Tsaraf K; Asraf K; Cohen-Ezra O; Likhter M; Mor O; Doolman R; Weiss-Ottolenghi Y; Hod T; Afek A; Kreiss Y; Lustig Y; Regev-Yochay G; Mandelboim M; Ben-Ari Z
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
    J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.